ABCC2 induces metabolic vulnerability and cellular ferroptosis via enhanced glutathione efflux in gastric cancer

Yiding Wang; Xuejun Gan; Xiaojing Cheng; Yongning Jia; Gangjian Wang; Xiaohuan Tang; Hong Du; Xiaomei Li; Xijuan Liu; Xiaofang Xing; Jiafu Ji; Ziyu Li

doi:10.1002/ctm2.1754

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (8) : e1754 DOI: 10.1002/ctm2.1754

RESEARCH ARTICLE

ABCC2 induces metabolic vulnerability and cellular ferroptosis via enhanced glutathione efflux in gastric cancer

Yiding Wang ¹^,²
, Xuejun Gan ¹^,²
, Xiaojing Cheng ¹
, Yongning Jia ²
, Gangjian Wang ¹^,²
, Xiaohuan Tang ¹^,²
, Hong Du ¹
, Xiaomei Li ¹
, Xijuan Liu ³
, Xiaofang Xing ¹^,^†
, Jiafu Ji ¹^,²^,^†
, Ziyu Li ¹^,²^,^†

Author information +

History +

PDF

Abstract

	•ABCC2 plays a crucial role in inducing metabolic vulnerability and ferroptosis in gastric cancer through enhanced glutathione efflux.
	•The ABCC2 24C > T polymorphism is a key factor influencing its expression.
	•These results highlight the potential of ABCC2 as a predictive biomarker and therapeutic target in gastric cancer.

Keywords

ABCC2 / amino acid metabolism / ferroptosis / gastric cancer / glutathione

Cite this article

Download citation ▾

Yiding Wang, Xuejun Gan, Xiaojing Cheng, Yongning Jia, Gangjian Wang, Xiaohuan Tang, Hong Du, Xiaomei Li, Xijuan Liu, Xiaofang Xing, Jiafu Ji, Ziyu Li. ABCC2 induces metabolic vulnerability and cellular ferroptosis via enhanced glutathione efflux in gastric cancer. Clinical and Translational Medicine, 2024, 14(8): e1754 DOI:10.1002/ctm2.1754

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[2]	FerlayJ, Soerjomataram I, DikshitR, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.

[3]	YangL, YingX, LiuS, et al. Gastric cancer: epidemiology, risk factors and prevention strategies. Chin J Cancer Res. 2020;32(6):695-704.

[4]	SastreJ, Garcia-Saenz JA, Diaz-RubioE. Chemotherapy for gastric cancer. World J Gastroenterol. 2006;12(2):204-213.

[5]	JimMA, Pinheiro PS, CarreiraH, EspeyDK, Wiggins CL, WeirHK. Stomach cancer survival in the United States by race and stage (2001-2009):findings from the CONCORD-2 study. Cancer. 2017;123(24):4994-5013.

[6]	LiZ, XingX, ShanF, et al. ABCC2-24C >T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. Oncotarget. 2016;7(34):55449-55457.

[7]	KepplerD, LeierI, JedlitschkyG. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem. 1997;378(8):787-791.

[8]	BorstP, EversR, KoolM, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295-1302.

[9]	BorstP, EversR, KoolM, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta. 1999;1461(2):347-357.

[10]	HinoshitaE, Uchiumi T, TaguchiK, et al. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res. 2000;6(6):2401-2407.

[11]	HanS-H, KimJW, KimM, et al. Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy. Oncol Lett. 2019;17(6):5572-5580.

[12]	TheileD, Grebhardt S, HaefeliWE, WeissJ. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol. 2009;78(11):1366-1373.

[13]	JiB, ItoK, SekineS, Tajima A, HorieT. Ethacrynic-acid-induced glutathione depletion and oxidative stress in normal and Mrp2-deficient rat liver. Free Radic Biol Med. 2004;37(11):1718-1729.

[14]	ShaR, XuY, YuanC, et al. Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. EBioMedicine. 2021;71:103560.

[15]	AndreoliSP, Mallett CP, BergsteinJM. Role of glutathione in protecting endothelial cells against hydrogen peroxide oxidant injury. J Lab Clin Med. 1986;108(3):190-819.

[16]	DickinsonDA, FormanHJ. Glutathione in defense and signaling: lessons from a small thiol. Ann N Y Acad Sci. 2002;973:488-504.

[17]	YangWS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26(3):165-176.

[18]	XieY, HouW, SongX, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369-379.

[19]	GaoM, YiJ, ZhuJ, et al. Role of mitochondria in ferroptosis. Mol Cell. 2019;73(2):354-363. e3.

[20]	LiZ, GaoX, PengX, et al. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Sci Adv. 2020;6(9):eaay4211.

[21]	FanK, CaoC, PanY, et al. Magnetoferritin nanoparticles for targeting and visualizing tumour tissues. Nat Nanotechnol. 2012;7(7):459-464.

[22]	YinS, YuY, WuN, et al. Patient-derived tumor-like cell clusters for personalized chemo-and immunotherapies in non-small cell lung cancer. Cell stem cell. 2024;31(5):717-733. e8.

[23]	GuD, ZhengR, XinJ, et al. Evaluation of GWAS-identified genetic variants for gastric cancer survival. EBioMedicine. 2018;33:82-87.

[24]	HanJY, LimHS, YooYK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007;110(1):138-147.

[25]	SunN, SunX, ChenB, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65(3):437-446.

[26]	DeplanckeB, AlpernD, GardeuxV. The genetics of transcription factor DNA binding variation. Cell. 2016;166(3):538-554.

[27]	WangJQ, YangY, CaiCY, et al. Multidrug resistance proteins (MRPs):structure, function and the overcoming of cancer multidrug resistance. Drug Resist Updat. 2021;54:100743.

[28]	ZhengJ, ConradM. The metabolic underpinnings of ferroptosis. Cell Metab. 2020;32(6):920-937.

[29]	AlborziniaH, Flórez AF, KrethS, et al. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nature Cancer. 2022;3(4):471-485.

[30]	YuX, LongYC. Crosstalk between cystine and glutathione is critical for the regulation of amino acid signaling pathways and ferroptosis. Sci Rep. 2016;6:30033.

[31]	ShinCS, MishraP, WatrousJD, et al. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8:15074.

[32]	NochEK, PalmaL, YimI, et al. Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production. Proc Nat Acad Sci USA. 2024;121(8):e2317343121.

[33]	LiAM, YeJ. Reprogramming of serine, glycine and one-carbon metabolism in cancer. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165841.

[34]	JainM, Nilsson R, SharmaS, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012;336(6084):1040-1044.

[35]	YoonSJ, CombsJA, FalzoneA, et al. Comprehensive metabolic tracing reveals the origin and catabolism of cysteine in mammalian tissues and tumors. Cancer Res. 2023;83(9):1426-1442.

[36]	BansalA, SimonMC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018;217(7):2291-2298.

[37]	ZhaoL, PengY, HeS, et al. Apatinib induced ferroptosis by lipid peroxidation in gastric cancer. Gastric Cancer. 2021;24(3):642-654.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.